Exercise and supplements for transthyretin heart disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests whether a program of exercise and special nutritional supplements can help people aged 70 and older with transthyretin cardiac amyloidosis—a condition where abnormal proteins build up in the heart. It aims to see if this combination can improve heart function and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years of age or older.
- You have been diagnosed with a specific type of heart disease called transthyretin cardiac amyloidosis.
- Your health has been stable for the past month.
- Your doctor has cleared you to do moderate exercise.
- You do not have severe memory problems, kidney failure needing dialysis, or a life-threatening illness expected to last less than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This study tests a new type of heart imaging scan called [68Ga]Ga-FAPI-46 PET to help doctors see and track transthyretin cardiac amyloidosis (a disease where abnormal proteins damage the heart). The scan may help identify which patients are getting worse.
This study tests whether a supervised exercise and rehabilitation program can help people with a specific type of heart amyloidosis (ATTRwt) feel better and improve their heart function. It may be a good fit if you have stable heart failure and can safely exercise.
This study looks at whether a 5-week supervised exercise and education program can help people with a specific type of heart amyloidosis (ATTR) feel better and improve their heart function. It will check your exercise ability and heart health before and after the program.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Hear when a new Transthyretin Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.